REGENXBIO Inc. vs Relmada Therapeutics, Inc. — Valuation Comparison 2026
Access all valuation models for RGNX vs RLMD — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →RGNX scores higher with a 6.4/10 quality rating vs RLMD's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing REGENXBIO Inc. (RGNX) and Relmada Therapeutics, Inc. (RLMD) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
RGNX currently trades at $6.89 with a QOC of 6.4/10, while RLMD trades at $7.25 with a QOC of 4.4/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).